company background image
VCYT logo

Veracyte NasdaqGM:VCYT Stock Report

Last Price

US$21.72

Market Cap

US$1.6b

7D

0.5%

1Y

1.2%

Updated

27 Mar, 2024

Data

Company Financials +

VCYT Stock Overview

Veracyte, Inc. operates as a diagnostics company in the United States and internationally.

VCYT fundamental analysis
Snowflake Score
Valuation3/6
Future Growth1/6
Past Performance0/6
Financial Health6/6
Dividends0/6

Veracyte, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Veracyte
Historical stock prices
Current Share PriceUS$21.72
52 Week HighUS$30.52
52 Week LowUS$19.52
Beta1.63
1 Month Change-7.81%
3 Month Change-24.11%
1 Year Change1.16%
3 Year Change-59.59%
5 Year Change-12.35%
Change since IPO63.92%

Recent News & Updates

Recent updates

Lacklustre Performance Is Driving Veracyte, Inc.'s (NASDAQ:VCYT) Low P/S

Apr 18
Lacklustre Performance Is Driving Veracyte, Inc.'s (NASDAQ:VCYT) Low P/S

A Look At The Intrinsic Value Of Veracyte, Inc. (NASDAQ:VCYT)

Mar 18
A Look At The Intrinsic Value Of Veracyte, Inc. (NASDAQ:VCYT)

Veracyte Percepta Genomic Sequencing Classifier demonstrates accuracy in lung cancer risk

Jul 13

Veracyte: Not A Healthy Diagnosis

May 12

Valuing Veracyte Stock

Oct 03

Shareholder Returns

VCYTUS BiotechsUS Market
7D0.5%0.9%0.4%
1Y1.2%10.3%28.8%

Return vs Industry: VCYT underperformed the US Biotechs industry which returned 9.6% over the past year.

Return vs Market: VCYT underperformed the US Market which returned 29.5% over the past year.

Price Volatility

Is VCYT's price volatile compared to industry and market?
VCYT volatility
VCYT Average Weekly Movement7.5%
Biotechs Industry Average Movement11.6%
Market Average Movement6.0%
10% most volatile stocks in US Market16.9%
10% least volatile stocks in US Market3.0%

Stable Share Price: VCYT's share price has been volatile over the past 3 months.

Volatility Over Time: VCYT's weekly volatility (8%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2006815Marc Stapleyhttps://www.veracyte.com

Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; Percepta Nasal Swab Test for lung cancer diagnosis; and Envisia Genomic Classifier for diagnosing interstitial lung disease, including idiopathic pulmonary fibrosis. It is also developing Envisia Classifier, the nCounter analysis system; and LymphMark for lymphoma subtyping test.

Veracyte, Inc. Fundamentals Summary

How do Veracyte's earnings and revenue compare to its market cap?
VCYT fundamental statistics
Market capUS$1.63b
Earnings (TTM)-US$74.40m
Revenue (TTM)US$361.05m

4.5x

P/S Ratio

-21.9x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
VCYT income statement (TTM)
RevenueUS$361.05m
Cost of RevenueUS$112.90m
Gross ProfitUS$248.15m
Other ExpensesUS$322.55m
Earnings-US$74.40m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-0.99
Gross Margin68.73%
Net Profit Margin-20.61%
Debt/Equity Ratio0%

How did VCYT perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.